Skip to content

Comparison of Tramadol vs Remifentanyl Patient Controlled Analgesia for Second Trimester Abortions

Randomized Double Blind Study Comparing Patient Controlled Analgesia With Tramadol vs. Remifentanyl for Women Undergoing 2nd Trimester Abortions

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00361686
Enrollment
40
Registered
2006-08-08
Start date
2006-01-31
Completion date
2007-01-31
Last updated
2015-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abortion,Induced

Keywords

tramadol, remifentanyl, patient controlled analgesia, abortion

Brief summary

Patients undergoing second trimester abortions will recieve either patient controlled analgesia with either remifentanyl or tramadol for pain alleviation. We beleive both to be equally effective for pain alleviation.

Detailed description

Women undergoing second trimester abortions will recieve patient controlled analgesia eith either tramadol or remifentanyl. Patients will not know what they are recieving. Patients in the tramadol goup will get a loading dose of tramadol and metocloparamide while the women in the remifentanyl group will be given a loading placebo. Women will then be attached to one of the two patinet controlled analgesia protocols. Throughout their laboring process they will be monitored for blood pressure, pulse, breathing rate, sedation score and nausea. Additional medicatyion will be given for nausea. If woman are still in pain the patient controlled analgesia settings will be set to deliver a higher dose. If the woman remains in pain, she will be given an additional per os medication.If this still does not alleviate pain, the option of epidural analgesia will be offered.

Interventions

DRUGtramadol
DEVICEpatient contolled analgesia

Sponsors

Rabin Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

Woman undergoing 2nd trimester abortion -

Exclusion criteria

* Seizure disorder \- \* Psychiatric disorder * Inability to recieve patient controlled analgesia * Allergy to tramadol or remifentanyl

Design outcomes

Primary

MeasureTime frame
Satisfaction
VAS scores
Nausea
Sedation

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026